Forss, Anders http://orcid.org/0000-0002-1906-4982
Clements, Mark
Myrelid, Pär
Strid, Hans
Söderman, Charlotte
Wagner, Agnieszka
Andersson, David
Hjelm, Fredrik
,
Olén, Ola
Halfvarson, Jonas
Ludvigsson, Jonas F.
Funding for this research was provided by:
Janssen Cilag AB
Karolinska Institute
Article History
Received: 18 January 2022
Accepted: 24 March 2022
First Online: 22 April 2022
Declarations
:
: PM served as speaker and/or advisory board member for AbbVie, Ferring, Janssen, Pfizer, Takeda, Baxter, and Tillotts Pharma. HS served as speaker and/or advisory board member for AbbVie, Ferring, Janssen, Pfizer, Takeda, Gilead, and Tillotts Pharma. DA served as speaker and/or advisory board member for AbbVie, Janssen, and Takeda. FH is an employee of Janssen Cilag AB, Sweden. OO has been PI on projects at Karolinska Institutet, partly financed by investigator-initiated grants from Janssen and Ferring, and Karolinska Institutet has received fees for lectures and participation on advisory boards from Janssen, Ferring, Takeda, and Pfizer. OO also reports a grant from Pfizer in the context of a national safety monitoring program. JH served as speaker and/or advisory board member for AbbVie, Celgene, Celltrion, Dr. Falk Pharma and the Falk Foundation, Ferring, Hospira, Janssen, MEDA, Medivir, MSD, Olink Proteomics, Pfizer, Prometheus Laboratories, Sandoz/Novartis, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB and received grant support from Janssen, MSD, and Takeda.
: This study was performed in line with the principles of the Declaration of Helsinki. All study participants signed an informed consent authorizing the use of data collected in this study. This project was approved by the Regional Ethical Review Board in Linköping, Sweden (2017–290-31).